Volatile anesthetics inhibit dihydropyridine binding to malignant hyperthermia-susceptible and normal pig skeletal muscle membranes

Anesthesiology. 1994 Mar;80(3):618-24. doi: 10.1097/00000542-199403000-00019.

Abstract

Background: Surface membrane dihydropyridine receptor Ca2+ channels may play a role in the response of malignant hyperthermia-susceptible skeletal muscle to volatile anesthetics.

Methods: We determined the effect of halothane, enflurane, and isoflurane on the binding of the Ca2+ channel blocker PN200-110 to skeletal muscle membranes isolated from malignant hyperthermia-susceptible and normal pigs.

Results: In the presence of 0.4 mM halothane, the maximal [3H]PN200-110 binding to both normal and malignant hyperthermia membranes was reduced by 37-43% (P < 0.05). There was no difference in the equilibrium constant for the halothane-dependent inhibition of [3H]PN200-110 binding to these two types of membranes. There also was no significant difference among halothane, enflurane, or isoflurane in their ability to inhibit [3H]PN200-110 binding to either normal or malignant hyperthermia membranes.

Conclusions: Volatile anesthetics inhibit the binding of PN200-110 to skeletal muscle membranes by decreasing the number of functionally active dihydropyridine receptor proteins. This inhibition is similar for membranes isolated from both normal and malignant hyperthermia-susceptible muscle, thus providing no evidence for a halothane-induced functional defect in this protein in malignant hyperthermia-susceptible muscle. However, the results of this study also indicate that the mechanism by which volatile anesthetics decrease surface membrane Ca2+ currents in skeletal muscle is by reducing the number of functional dihydropyridine receptor Ca2+ channels.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anesthetics / pharmacology*
  • Animals
  • Calcium Channel Blockers / metabolism
  • Calcium Channels / drug effects
  • Calcium Channels / metabolism
  • Calcium Channels, L-Type
  • Dihydropyridines / antagonists & inhibitors*
  • Dihydropyridines / metabolism*
  • Drug Interactions
  • Halothane / pharmacology
  • Isradipine / metabolism
  • Malignant Hyperthermia / genetics
  • Malignant Hyperthermia / metabolism*
  • Membranes / drug effects
  • Membranes / metabolism
  • Muscle Proteins / antagonists & inhibitors*
  • Muscle Proteins / drug effects
  • Muscle Proteins / metabolism*
  • Muscles / drug effects*
  • Muscles / metabolism*
  • Swine
  • Tritium

Substances

  • Anesthetics
  • Calcium Channel Blockers
  • Calcium Channels
  • Calcium Channels, L-Type
  • Dihydropyridines
  • Muscle Proteins
  • Tritium
  • Halothane
  • Isradipine